These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25643044)

  • 1. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
    Alkabbani W; Gamble JM
    Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
    Nisly SA; Kolanczyk DM; Walton AM
    Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
    Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
    Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
    Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
    Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
    Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
    Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
    Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
    J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
    Yang XP; Lai D; Zhong XY; Shen HP; Huang YL
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1149-58. PubMed ID: 25124541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
    Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
    J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
    Wang H; Yao G; Chen X; Ouyang J; Yang J
    Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
    Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
    J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
    Lamos EM; Younk LM; Davis SN
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):763-75. PubMed ID: 23590413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipragliflozin: first global approval.
    Poole RM; Dungo RT
    Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.